New drug development in digestive neuroendocrine tumors

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1307-1313

  Duran I ^a   Salazar, Ramon ^b   Casanovas, O ^b   Arrazubi, V ^b   Vilar, E ^c   Siu, L L ^a   Yao, J ^d   Tabernero, J ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antiangiogenic therapies; Carcinoid tumors; EGFR inhibitors; mTOR inhibitors; Neuroendocrine tumors; Targeted drug therapy

Indexed keywords

2 METHOXYESTRADIOL; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; BEVACIZUMAB; ENDOSTATIN; EVEROLIMUS; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MINOCYCLINE; MONOCLONAL ANTIBODY DC101; OCTREOTIDE; OXALIPLATIN; PEGINTERFERON ALPHA2B; PLACEBO; RAPAMYCIN; SEMAXANIB; SOMATOSTATIN DERIVATIVE; SORAFENIB; SU 10944; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMID; THALIDOMIDE; UNINDEXED DRUG; VATALANIB;

ABSENCE OF SIDE EFFECTS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM TUMOR; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; FATIGUE; GLOSSODYNIA; GRANULOCYTOPENIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS;

EID: 34250197654     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm009     Document Type: Review

References (57)

1. Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-138.
2. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 2005; 8: 299-309.
3. Papouchado B, Erickson LA, Rohlinger AL et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18: 1329-1335.
4. Hopfner M, Sutter AP, Gerst B et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003; 89: 1766-1775.
5. von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-4581.
6. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004; 136: 1297-1302.
7. Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol. 2002; 10: 139-146.
8. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537.
9. Parangi S, Dietrich W, Christofori G et al. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res 1995; 55: 6071-6076.
10. Casanovas O, Hager JH, Chun MG, Hanahan D. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene 2005; 24: 6597-6604.
11. Calender A, Vercherat C, Gaudray P, Chayvialle JA. Deregulation of genetic pathways in neuroendocrine tumors. Ann Oncol 2001; 12 (Suppl 2): S3-S11.
12. Parekh D, Ishizuka J, Townsend CM Jr et al. Characterization of a human pancreatic carcinoid in vitro: Morphology, amine and peptide storage, and secretion. Pancreas 1994; 9: 83-90.
13. Kolby L, Bernhardt P, Ahlman H et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 2001; 158: 745-755.
14. Modlin IM, Kidd M, Pfragner R et al. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 2006; 91: 2340-2348.
15. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 89-96.
16. Kerbel RS. Tumor angiogenesis: Past, present and the near future Carcinogenesis 2000; 21: 505-515.
17. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69 (Suppl 3): 46-56.
18. Bergers G, Javaherian K, Lo KM et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-812.
19. Wood JM, Bold G, Buchdunger E. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
20. Laird AD, Christensen JG, Li G et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002; 16: 681-690.
21. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
22. Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004; 9 (Suppl 1): 43-49.
23. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115-122.
24. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
25. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-952.
26. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295.
27. Yao JC, Ng C, Hoff PM et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 2005; 23 (Abstr 4007).
28. Aghajanian C. The role of bevacizumab in ovarian cancer-an evolving story. Gynecol Oncol 2006; 102: 131-133.
29. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
30. Kulke MH, Stuart K, Earle CC et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24 (Abstr 4044).
31. Dahut WL, Lakhani NJ, Gulley JL et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006; 5: 22-27.
32. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
33. Kulke M, Lenz HJ, Meropol NJ et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol 2005; 23 (Abstr 4008).
34. Bello C, Deprimo SE, Friece C et al. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol 2006; 24 (Abstr 4045).
35. Gross DJ, Munter G, Bitan M et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006; 13: 535-540.
36. Yao JC, Zhang JX, Rashid A. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007; 13 (1): 234-240.
37. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
38. Xu Y, Ellison C, Martin E et al. A phase II study of thalidomide in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002; 30b (Abstr 1931).
39. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401-406.
40. Kulke MH, Bergsland EK, Ryan DP et al, Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555-3561.
41. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29: 3-9.
42. Shah T, Hochhauser D, Frow R et al. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006; 18: 355-360.
43. Hobday TJ, Mahoney M, Erlichman C et al. Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2005; 23 (Abstr 4083).
44. Podsypanina K, Lee RT, Polltis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98: 10320-10325.
45. Johannessen CM, Reczek EE, James MF et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005; 102: 8573-8578.
46. Libutti SK, Choyke PL, Bartlett DL et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: Diagnostic and management recommendations. Surgery 1998, 124: 1153-1159.
47. Hammel PR, Vilgrain V, Terris B et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119: 1087-1095.
48. Kovatich A, Friedland DM, Druck T et al. Molecular alterations to human chromosome 3p loci neuroendocrine lung tumors. Cancer 1998: 83: 1109-1117.
49. Zhao J, Moch H, Scheidweiller AF et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 2001: 32: 364-372.
50. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor mTOR complex. Science 2005; 307: 1098-1101.
51. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005; 280: 40406-40416.
52. O'Reilly KE, Rojo F, She OB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
53. Raz I, Rubinger D, Popovtzer M et al. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. Diabetes 1998; 47: 924-930.
54. Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; In press.
55. Yao JC, Phan AT, Chang DZ et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2006; 24 (Abstr 4042).
56. Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006; 12: 3997-4003.
57. Di Cosimo S, Seoane J, Guzman M et al. Combination of the mammallan target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. J Clin Oncol 2005; 23 (Abstr 3112).